Evidence map›Paper›PMID 38327846›Full record

ArticleFrontiers in neuroscience2024

Auditory naming is impaired in posterior cortical atrophy and early-onset Alzheimer's disease.

Deepti Putcha, Ana Eustace, Nicole Carvalho, Bonnie Wong, Megan Quimby, Bradford C Dickerson

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Deepti PutchaFrontotemporal Disorders Unit and Alzheimer's Disease Research Center, Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, United States.
Ana EustaceFrontotemporal Disorders Unit and Alzheimer's Disease Research Center, Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, United States.
Nicole CarvalhoFrontotemporal Disorders Unit and Alzheimer's Disease Research Center, Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, United States.
Bonnie WongFrontotemporal Disorders Unit and Alzheimer's Disease Research Center, Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, United States.
Megan QuimbyFrontotemporal Disorders Unit and Alzheimer's Disease Research Center, Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, United States.
Bradford C DickersonFrontotemporal Disorders Unit and Alzheimer's Disease Research Center, Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, United States.

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Alberto Serrano-Pozo · 2019 to 2026
$36.5M
Project 4P41EB015896 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2012 to 2018
$9.8M
Imaging tau, amyloid, and neurodegeneration in PPAR01DC014296 · NIDCD · MASSACHUSETTS GENERAL HOSPITAL · PI DICKERSON, BRADFORD C, JOHNSON, KEITH A. · 2016 to 2020
$4.3M
Toward Personalized Prognosis and Outcomes in Primary Progressive AphasiaRF1NS131395 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI DICKERSON, BRADFORD C · 2023 to 2023
$2.5M
A Storage Area Network for Structural and Functional Image AnalysisS10RR023401 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI FISCHL, BRUCE · 2009 to 2009
$2.0M
SILICON GRAPHICS PRISM EXTREME 128P/1TBS10RR023043 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI SORENSEN, ALMA GREGORY · 2006 to 2006
$1.5M
Dissociating the mechanisms of Tau PET and cortical atrophy underlying memory deficits in typical and atypical prodromal Alzheimer's diseaseK23AG065450 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI PUTCHA, DEEPTI · 2020 to 2024
$1.0M
A Siemens MAGNETOTOM Trio 3 Tesla MRI SystemS10RR021110 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2006 to 2006
$500k
Tau Imaging in Atypical ADR21AG051987 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI DICKERSON, BRADFORD C, MCGINNIS, SCOTT MICHAEL · 2016 to 2017
$470k
Use of machine learning to quantify cognitive function in AD, FTD, and DLBR21AG073744 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI DICKERSON, BRADFORD C, WOLFF, PHILLIP MARK · 2021 to 2022
$443k
Computational psycholinguistic analysis of speech samples in PPA and AD and FTDR21DC019567 · NIDCD · MASSACHUSETTS GENERAL HOSPITAL · PI DICKERSON, BRADFORD C, WOLFF, PHILLIP MARK · 2022 to 2023
$443k
NCRR NIH HHS S10 RR021110NCRR NIH HHS S10 RR023043NCRR NIH HHS S10 RR023401NIA NIH HHS K23 AG065450NIA NIH HHS P30 AG062421NIA NIH HHS R21 AG051987NIA NIH HHS R21 AG073744NIBIB NIH HHS P41 EB015896NIDCD NIH HHS R01 DC014296NIDCD NIH HHS R21 DC019567NINDS NIH HHS RF1 NS131395
6 · The paper itself

Abstract

Introduction: Visual naming ability reflects semantic memory retrieval and is a hallmark deficit of Alzheimer's disease (AD). Naming impairment is most prominently observed in the late-onset amnestic and logopenic variant Primary Progressive Aphasia (lvPPA) syndromes. However, little is known about how other patients across the atypical AD syndromic spectrum perform on tests of auditory naming, particularly those with primary visuospatial deficits (Posterior Cortical Atrophy; PCA) and early onset (EOAD) syndromes. Auditory naming tests may be of particular relevance to more accurately measuring anomia in PCA syndrome and in others with visual perceptual deficits. Methods: Forty-six patients with biomarker-confirmed AD (16 PCA, 12 lvPPA, 18 multi-domain EOAD), at the stage of mild cognitive impairment or mild dementia, were administered the Auditory Naming Test (ANT). Performance differences between groups were evaluated using one-way ANOVA and Results: Based on published cutoffs, out of a total possible score of 50 on the ANT, 56% of PCA patients (mean score = 45.3), 83% of EOAD patients (mean = 39.2), and 83% of lvPPA patients (mean = 29.8) were impaired. Total uncued ANT performance differed across groups, with lvPPA performing most poorly, followed by EOAD, and then PCA. ANT performance was still impaired in lvPPA and EOAD after cuing, while performance in PCA patients improved to the normal range with phonemic cues. ANT performance was also directly correlated with measures of verbal fluency and working memory, and was associated with cortical atrophy in a circumscribed semantic language network. Discussion: Auditory confrontation naming is impaired across the syndromic spectrum of AD including in PCA and EOAD, and is likely related to auditory-verbal working memory and verbal fluency which represent the nexus of language and executive functions. The left-lateralized semantic language network was implicated in ANT performance. Auditory naming, in the absence of a visual perceptual demand, may be particularly sensitive to measuring naming deficits in PCA.

Indexed as

atypical ADconfrontation naminglogopenic variant primary progressive aphasianeuropsychologysemantic network

Identifiers

PMID38327846
PMCPMC10847232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.